Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Mexco Energy Corporation (MXC)

NYSE American - Nasdaq Real Time Price. Currency in USD
Add to watchlist
15.14-0.95 (-5.90%)
At close: 03:57PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close16.09
Open15.85
Bid12.45 x 1800
Ask19.00 x 900
Day's Range15.00 - 16.01
52 Week Range8.35 - 43.00
Volume8,518
Avg. Volume16,119
Market Cap32.122M
Beta (5Y Monthly)1.26
PE Ratio (TTM)N/A
EPS (TTM)-0.13
Earnings DateFeb 08, 2022 - Feb 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Mexco Energy Corporation Reports Financial Results for First Quarter

    MIDLAND, TX, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Mexco Energy Corporation (NYSE American: MXC) today reported net income of $1,298,672, or $0.59 per diluted share, for the quarter ending June 30, 2022, the Company’s first quarter of fiscal 2023, an increase of 340% versus $395,006 or $0.19 per diluted share, for the comparable quarter ending June 30, 2021. Operating revenues in the first quarter of fiscal 2023 increased 94% to $2,449,973 from $1,264,198 for the first quarter of fiscal 2022. This i

  • GlobeNewswire

    MEXCO ENERGY CORPORATION REPORTS FINANCIAL RESULTS FOR FISCAL 2022

    MIDLAND, TX, June 27, 2022 (GLOBE NEWSWIRE) -- Mexco Energy Corporation (NYSE American: MXC) reported results on its Annual Report, Form 10-K to the Securities and Exchange Commission for the fiscal year ended March 31, 2022. The Company reported net income of $2,855,066 or $1.36 per diluted share, for fiscal year 2022, compared to net income of $155,932, or $0.08 per diluted share, for fiscal 2021. Operating revenues in fiscal 2022 were $6,587,780, an increase of 135% when compared to fiscal 20

  • PR Newswire

    MGC Pharmaceuticals Enters Partnership with Sciensus Rare for Distribution of Cannabinoids to Treat Refractory Epilepsy, Dementia and Alzheimer's in the EU and UK

    MGC Pharmaceuticals Ltd. (LSE: MXC, ASX: MXC, OTC:MGCLF), a European based bio-pharma company specializing in the production and development of phytomedicines, has signed an exclusive distribution agreement with Sciensus Rare, a part of UK health care group, Sciensus, for the distribution of CannEpil® and CogniCann® in key European territories and the UK.

Advertisement
Advertisement